หน้าแรก
ค้นหา
Dr. Kolberg Discusses the LILAC Study of ABP 980
No description available
แสดงข้อมูลเพิ่มเติม 1
Dr. Kolberg Discusses the LILAC Study of ABP 980
Dr. Kolberg on the LILAC Study in Breast Cancer
LILAC: comparing cardiac safety of ABP 980 with trastuzumab
Dr. Kolberg Discusses the Central Pathology Review of ABP 980
Results from the LILAC study of ABP 980 with trastuzumab for HER2+ early breast cancer
Dr. Kolberg Discusses Next Steps with ABP 980
Dr. Kolberg on the Cardiac Safety of ABP 980
Dr. Kolberg Explains the Approval Process for Biosimilars
Dr. Kolberg Discusses Considerations With FDA-Approved Biosimilars
Dr. Kolberg on Ensuring Confidence With Biosimilars in Oncology
ABP 980, a trastuzumab biosimilar in combination with pertuzumab
Dr. Kolberg on Collecting Real-World Biosimilar Trastuzumab Data in Breast Cancer
Dr. Kolberg Provides a Global Perspective on Biosimilar Integration
ABP 980, a biosimilar antibody for trastuzumab
Dr. Kolberg on the Safety Profile of Trastuzumab Biosimilars in Breast Cancer
ASCO 2022: Biomarkertests beim hormonrezeptor-positiven metastasierten Brustkrebs, PD Dr. Kolberg
Hans-Christian Kolberg, MD: The Importance of Reporting Data on Biosimilar Trastuzumab
SABCS 2018: "Die zielgerichtete intraoperative Strahlentherapie", PD Dr. Kolberg
Dr. med. Hans-Christian Kolberg:
The importance of central pathology pCR review in an international multicenter neoadjuvant study...
